glp-1 and gip dual agonist TrimRX GIPR/GLP-1R dual agonist therapies for

Risk of severe COVID-1352 19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study 1353 including 8.3 million people

GLP-1 medications, with brand names such as Ozempic, Wegovy, and Zepbound, regulate blood sugar in people with type 2 diabetes and are also used for weight loss

Several GLP-1 receptor agonists have also demonstrated cardiovascular benefits in patients at high risk, although this is not a universal finding, as described later (2430)

(2025) Zepbound (Tirzepatide) injection (2025) Ania M

These medications represent a significant advancement in care by helping to regulate blood sugar, reduce appetite, and support healthy weight loss

TRIUMPH-3 (NCT05882045) will investigate change in bodyweight in people with overweight/obesity and cardiovascular disease, and TRIUMPH-4 (NCT05931367) will assess change in WOMAC score and bodyweight in individuals with overweight/obesity and knee OA